Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial

Journal of Nutritional Science

Volumn 4, Issue , 2015, Pages

  Minami, Jun Ichi ^a   Kondo, Shizuki ^a   Yanagisawa, Naotake ^a   Odamaki, Toshitaka ^a   Xiao, Jin Zhong ^a   Abe, Fumiaki ^a   Nakajima, Shigeru ^b   Hamamoto, Yukie ^b   Saitoh, Sanae ^c   Shimoda, Taeko ^c  

^a MORINAGA MILK INDUSTRY CO LTD   (Japan)

^b Nakajima Clinic   (Japan)

^c TOKYO HEALTHCARE UNIVERSITY   (Japan)

Author keywords

Bifidobacterium; Metabolic syndrome; Obesity; Randomised controlled trials

Indexed keywords

C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; PROBIOTIC AGENT;

ADULT; ARTICLE; BIFIDOBACTERIUM BREVE; BODY COMPOSITION; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FAT MASS; FEMALE; FOOD INTAKE; HEMATOLOGICAL PARAMETERS; HUMAN; LIVER FUNCTION; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84994607986     PISSN: 20486790     EISSN: None     Source Type: Journal    
DOI: 10.1017/jns.2015.5     Document Type: Article

References (46)

1. Haslam DW & James WPT (2005) Obesity. Lancet 366, 1197-1209.
2. Mekkes MC, Weenen TC, Brummer RJ, et al. (2013) The development of probiotic treatment in obesity: a review. Benef Microbes 5, 19-28.
3. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. (2009) A core gut microbiome in obese and lean twins. Nature 457, 480-484.
4. Zhang H, DiBaise JK, Zuccolo A, et al. (2009) Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 106, 2365-2370.
5. Ley RE, Turnbaugh PJ, Klein S, et al. (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023.
6. Esteve E, Ricart W & Fernández-Real JM (2011) Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? Curr Opin Clin Nutr Metab Care 14, 483-490.
7. Musso G, Gambino R & Cassader M (2010) Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care 33, 2277-2284.
8. Kalliomäki M, Collado MC, Salminen S, et al. (2008) Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 87, 534-538.
9. Collado MC, Isolauri E, Laitinen K, et al. (2008) Distinct composition of gut microbiota during pregnancy in overweight and normalweight women. Am J Clin Nutr 88, 894-899.
10. Wu X, Ma C, Han L, et al. (2010) Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 61, 69-78.
11. Cani PD, Neyrinck AM, Fava F, et al. (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50, 2374-2383.
12. Cani PD, Amar J, Iglesias MA, et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772.
13. Ilmonen J, Isolauri E, Poussa T, et al. (2011) Impact of dietary counselling and probiotic intervention on maternal anthropometric measurements during and after pregnancy: a randomized placebocontrolled trial. Clin Nutr 30, 156-164.
14. Mikirova NA, Casciari JJ, Hunninghake RE, et al. (2011) Effect of weight reduction on cardiovascular risk factors and CD34-positive cells in circulation. Int J Med Sci 8, 445-452.
15. Kadooka Y, Sato M, Ogawa A, et al. (2013) Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. Br J Nutr 110, 1696-1703.
16. Sanz Y, Santacruz A & Gauffin P (2010) Gut microbiota in obesity and metabolic disorders. Proc Nutr Soc 69, 434-441.
17. Kadooka Y, Sato M, Imaizumi K, et al. (2010) Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr 64, 636-643.
18. Delzenne NM, Neyrinck AM & Cani PD (2013) Gut microbiota and metabolic disorders: how prebiotic can work? Br J Nutr 109, S81-S85.
19. Yin YN, Yu QF, Fu N, et al. (2010) Effects of four bifidobacteria on obesity in high-fat diet induced rats. World J Gastroenterol 16, 3394-3401.
20. Kondo S, Xiao JZ, Satoh T, et al. (2010) Antiobesity effects of Bifidobacterium breve strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. Biosci Biotechnol Biochem 74, 1656-1661.
21. Montague CT & O'Rahilly S (2000) The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49, 883-888.
22. Fox CS, Massaro JM, Hoffmann U, et al. (2007) Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116, 39-48.
23. Bennett WL, Maruthur NM, Singh S, et al. (2011) Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154, 602-613.
24. Nakanishi N, Suzuki K & Tatara K (2004) Serum γ-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 27, 1427-1432.
25. Lee JH, Um MH & Park YK (2013) The association of metabolic syndrome and serum γ-glutamyl transpeptidase: a 4-year cohort study of 3,698 Korean male workers. Clin Nutr Res 2, 67-75.
26. Lieber CS (1984) Alcohol and the liver: 1984 update. Hepatology 4, 1243-1260.
27. Sato KK, Hayashi T, Nakamura Y, et al. (2008) Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care 31, 1230-1236.
28. Miller PM, Anton RF, Egan BM, et al. (2005) Excessive alcohol consumption and hypertension: clinical implications of current research. J Clin Hypertens (Greenwich) 7, 346-351.
29. Lee DH, Ha MH, Kim JH, et al. (2003) γ-Glutamyltransferase and diabetes - a 4 year follow-up study. Diabetologia 46, 359-364.
30. Lee DH, Silventoinen K, Jacobs DR, et al. (2004) γ-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 89, 5410-5414.
31. Fraser A, Harris R, Sattar N, et al. (2007) γ-Glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 27, 2729-2735.
32. Aller R, De Luis DA, Izaola O, et al. (2011) Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 15, 1090-1095.
33. Kirpich IA, Solovieva NV, Leikhter SN, et al. (2008) Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 42, 675-682.
34. Kondo S, Kamei A, Xiao JZ, et al. (2013) Bifidobacterium breve B-3 exerts metabolic syndrome-suppressing effects in the liver of diet-induced obese mice: a DNA microarray analysis. Benef Microbes 4, 247-251.
35. Baker RG, Hayden MS & Ghosh S (2011) NF-κB, inflammation, and metabolic disease. Cell Metab 13, 11-22.
36. Schenk S, Saberi M & Olefsky JM (2008) Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118, 2992-3002.
37. Hotamisligil GS & Erbay E (2008) Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 8, 923-934.
38. Rocha VZ & Folco EJ (2011) Inflammatory concepts of obesity. Int J Inflam 2011, 529061.
39. Weisberg SP, McCann D, Desai M, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112, 1796-1808.
40. Suganami T & Ogawa Y (2010) Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol 88, 33-39.
41. Suganami T, Nishida J & Ogawa Y (2005) A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor α. Arterioscler Thromb Vasc Biol 25, 2062-2068.
42. Cani PD, Bibiloni R, Knauf C, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470-1481.
43. Cani PD, Possemiers S, Van de Wiele T, et al. (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091-1103.
44. Hoarau C, Lagaraine C, Martin L, et al. (2006) Supernatant of Bifidobacterium breve induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway. J Allergy Clin Immunol 117, 696-702.
45. Bermudez-Brito M, Muñoz-Quezada S, Gomez-Llorente C, et al. (2013) Cell-free culture supernatant of Bifidobacterium breve CNCM I-4035 decreases pro-inflammatory cytokines in human dendritic cells challenged with Salmonella typhi through TLR activation. PLOS ONE 8, e59370.
46. Jeon SG, Kayama H, Ueda Y, et al. (2012) Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog 8, e1002714.